drugset / Trial / NCT03280173

A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood

NCT03280173

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

2 different formulations of tafamidis will be compared under both fed and fasted conditions. Subjects will be fasted overnight or fed. After swallowing one of the tafamidis formulations, tafamidis blood concentrations will be measured periodically for 8 days. After 16 days, subjects will take a different formulation in the fed or fasted state or take the same formulation in the opposite feeding condition. This will be repeated, 16 days apart, until all subjects have taken each formulation both fed and fasted.

Timeline

Start
2017-09-29
Primary completion
2018-02-23
Completion
2018-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 61 mg Oral
Subject Tafamidis Unknown 80 mg Oral

Indications

No indication recorded.